Back to search results

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Metastatic Leiomyosarcoma · Unresectable Leiomyosarcoma · Bone Sarcoma · Translocation-associated Soft Tissue Sarcoma · Synovial Sarcomas · Osteosarcoma Metastatic · Ewing Sarcoma · Ewing Sarcoma Metastatic · Sarcoma Metastatic · Sarcoma of Bone

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Northwestern University, Chicago, Illinois, United States

    Contact: Study coordinator (Pedro Hermida de Viveiros) · cancer@northwestern.edu · (312) 926-9636
    Contact: Principal Investigator (Pedro Hermida de Viveiros, MD)
Study leads

  • Pedro Hermida de Viveiros, MD

    Principal Investigator

    Northwestern University

View source on ClinicalTrials.gov(opens in a new tab)